Insmed Launches Brinsupri Tablet in Japan for Non-Cystic Fibrosis Bronchiectasis

07:54 AM EDT, 10/19/2026 (MT Newswires) -- Insmed (INSM) said Monday that it is launching a 25 mg tablet of Brinsupri in Japan to treat non-cystic fibrosis bronchiectasis, or NCFB, in adults and pediatric patients aged at least 12 years. The company said that the once-daily tablet is available in the country by prescription. Brinsupri was approved by Japan's Ministry of Health, Labour, and Welfare to treat NCFB, a chronic lung condition, in August, it added.